Literature DB >> 11905819

Towards a blood-stage vaccine for malaria: are we following all the leads?

M F Good1.   

Abstract

Although the malaria parasite was discovered more than 120 years ago, it is only during the past 20 years, following the cloning of malaria genes, that we have been able to think rationally about vaccine design and development. Effective vaccines for malaria could interrupt the life cycle of the parasite at different stages in the human host or in the mosquito. The purpose of this review is to outline the challenges we face in developing a vaccine that will limit growth of the parasite during the stage within red blood cells--the stage responsible for all the symptoms and pathology of malaria. More than 15 vaccine trials have either been completed or are in progress, and many more are planned. Success in current trials could lead to a vaccine capable of saving more than 2 million lives per year.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11905819     DOI: 10.1038/35100540

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  38 in total

1.  The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria.

Authors:  Morris O Makobongo; George Riding; Huji Xu; Chakrit Hirunpetcharat; Dianne Keough; John de Jersey; Peter Willadsen; Michael F Good
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-19       Impact factor: 11.205

2.  Conservation of Babesia bovis small heat shock protein (Hsp20) among strains and definition of T helper cell epitopes recognized by cattle with diverse major histocompatibility complex class II haplotypes.

Authors:  Junzo Norimine; Juan Mosqueda; Guy H Palmer; Harris A Lewin; Wendy C Brown
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

Review 3.  Malaria.

Authors:  Christopher J M Whitty; Mark Rowland; Frances Sanderson; Theonest K Mutabingwa
Journal:  BMJ       Date:  2002-11-23

4.  Plasmodium falciparum: a simplified technique for obtaining singly infected erythrocytes.

Authors:  Manoj K Puthia; Kevin S W Tan
Journal:  Parasitol Res       Date:  2004-12-23       Impact factor: 2.289

5.  A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1.

Authors:  Paulo Afonso Nogueira; Fabiana Piovesan Alves; Carmen Fernandez-Becerra; Oliver Pein; Neida Rodrigues Santos; Luiz Hildebrando Pereira da Silva; Erney Plessman Camargo; Hernando A del Portillo
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

6.  Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

Authors:  Matthew B McCarra; George Ayodo; Peter O Sumba; James W Kazura; Ann M Moormann; David L Narum; Chandy C John
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

7.  A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.

Authors:  A Rainczuk; T Scorza; T W Spithill; P M Smooker
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Lack of an association between antibodies to Plasmodium falciparum glycosylphosphatidylinositols and malaria-associated placental changes in Cameroonian women with preterm and full-term deliveries.

Authors:  Amorsolo L Suguitan; D Channe Gowda; Genevieve Fouda; Lucy Thuita; Ainong Zhou; Rosine Djokam; Simon Metenou; Rose G F Leke; Diane Wallace Taylor
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

9.  A Chimeric Plasmodium vivax Merozoite Surface Protein Antibody Recognizes and Blocks Erythrocytic P. cynomolgi Berok Merozoites In Vitro.

Authors:  Fei-Hu Shen; Jessica Jie Ying Ong; Yang Cheng; Yi-Fan Sun; Yao Lei; Rui-Lin Chu; Kokouvi Kassegne; Hai-Tian Fu; Cheng Jin; Eun-Taek Han; Bruce Russell; Jin-Hee Han
Journal:  Infect Immun       Date:  2021-01-19       Impact factor: 3.441

10.  Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea.

Authors:  Leanne J Robinson; Marthe C D'Ombrain; Danielle I Stanisic; Jack Taraika; Nicholas Bernard; Jack S Richards; James G Beeson; Livingstone Tavul; Pascal Michon; Ivo Mueller; Louis Schofield
Journal:  Infect Immun       Date:  2009-04-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.